Gilead Sciences, Inc.
GILDHealthcareNASDAQDrug Manufacturers - General · Last scanned Sep 8, 2026
Scan Results
Daily timeframeGilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. At a $187.23B market cap, Gilead Sciences, Inc. ranks as a large-cap company within healthcare. The company provides Biktarvy, Descovy, Genvoya, Odefsey, Sunlenca, Symtuza, and YeztugoFor the treatment of HIV-1 infection in patients.
Market Cap
$187.23B
Beta
0.35
P/E (TTM)
—
P/E (Fwd)
15.27
EPS (TTM)
$-2.66
EPS (Fwd)
$9.89
ROE
-20.7%
ROA
14.1%
Cash
$4.88B
Total Debt
$26.25B
Free CF
$9.77B
52W Change
30.4%
Annual Financials
Cash vs Debt
Where GILD stands vs its 150-day and 200-day moving averages
As of the September 3, 2026 close, GILD finished 9.64% above its 150-day moving average ($136.45) and 12.41% above its 200-day moving average ($133.09). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is GILD overbought or oversold?
At the September 3, 2026 close, GILD's RSI(14) was 70.4, in overbought territory (above 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
On the balance sheet, GILD has $4.88B in cash with $26.25B in obligations. The ability to service this debt comfortably depends on continued operational cash generation. Annual free cash flow of $9.77B supports ongoing capital allocation decisions and provides a cushion against unexpected expenses or downturns. Return on equity stands at -20.7%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Return on assets of 14.1% further supports the picture of efficient asset utilization. Revenue has been relatively flat, moving from $27.28B (2022) to $29.44B (2025).
The relatively low beta of 0.35 suggests GILD is a less volatile holding compared to the broader index. Debt significantly exceeds cash reserves, which means the company's financial flexibility could be constrained during economic downturns. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing GILD.